FeesSafety
Pluang+

China approves SYVIK® for treating two autoimmune blood disorders, expanding HUTCHMED's immunology portfolio.

Market News
19 Nov 2026, 12:00 WIB
GlobeNewsWire
View Source
Bullish
China approves SYVIK® for treating two autoimmune blood disorders, expanding HUTCHMED's immunology portfolio.

HUTCHMED announced that China's NMPA approved SYVIK® (sovleplenib), a novel Syk inhibitor, for treating adult patients with chronic primary Immune Thrombocytopenia (ITP) and Warm Antibody Autoimmune Hemolytic Anemia (wAIHA). The approvals are based on positive Phase III and II/III trial results showing SYVIK®'s effectiveness and safety in patients unresponsive to prior treatments. This marks HUTCHMED's first immunology drug approval, broadening its portfolio beyond oncology. The company plans to make SYVIK® accessible across China and is exploring global development opportunities, supported by orphan drug designation granted by the US FDA.

HUTCHMED's announcement of SYVIK® approval for immune conditions is presented here with Pluang's Health sector market data as of Nov 19, 2026, 15:02 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 83 rose and 62 fell today. Notable movers include ACB at USD 4.29 with a 1-day change of -5.09% and 100% sell order activity, HCA at USD 478.19 with a 1-day change of -4.59% and 100% buy order activity, and HLN at USD 8.72 with a 1-day change of -3.96%.

More News

A Race Against Blindness relaunches holiday fundraiser with $125K family prize package including Toyota Sienna and Disney vacation

A Race Against Blindness relaunches holiday fundraiser with $125K family prize package including Toyota Sienna and Disney vacation

A Race Against Blindness has brought back its popular Miles, Magic & Mochas holiday fundraiser, offering supporters a chance to win a prize package valued at $125,000. The package includes a 2026 Toyota Sienna Platinum, a $20,000 Disney vacation awar...

Neutral
53 minutes ago
Shell buys back over 2 million shares as part of its ongoing repurchase program.

Shell buys back over 2 million shares as part of its ongoing repurchase program.

On November 18, 2026, Shell plc repurchased a total of approximately 2.15 million shares across multiple trading venues including the London Stock Exchange and European markets. These shares are being bought back for cancellation under Shell's existi...

Company Fundamentals
Neutral
59 minutes ago
MercadoLibre and Amazon show strong long-term growth despite short-term profit challenges.

MercadoLibre and Amazon show strong long-term growth despite short-term profit challenges.

MercadoLibre and Amazon have both delivered impressive returns over the past decade by continuously growing their customer base, revenue, and profits. MercadoLibre is deliberately sacrificing short-term profits to invest in long-term growth, expandin...

Market News
Bullish
1 hour ago
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a strong track record for investors. The company faces challenges like a patent cliff, costly acquisitions, and clinical setbacks that could threaten this strea...

Company Fundamentals
Neutral
1 hour ago
General Mills and Realty Income offer high dividend yields as their stock prices near 52-week lows.

General Mills and Realty Income offer high dividend yields as their stock prices near 52-week lows.

General Mills and Realty Income are trading near their 52-week lows, presenting attractive dividend yields of about 7% and 5.7% respectively. General Mills has a strong dividend history of 127 years and covers its dividend with free cash flow despite...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App